Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Johnson & Johnson to acquire Proteologix for $850 million

Published 05/16/2024, 09:44 PM

NEW BRUNSWICK, N.J. - Johnson & Johnson (NYSE: JNJ) announced it will acquire biotechnology firm Proteologix, Inc. for $850 million in cash, with the potential for additional milestone payments. The transaction, subject to customary closing conditions and antitrust clearance, is expected to close by mid-year 2024.

Proteologix specializes in bispecific antibodies for the treatment of immune-mediated diseases, including atopic dermatitis (AD) and asthma. Its portfolio features two promising bispecific antibodies, PX128 and PX130, targeting different disease pathways. PX128 is ready to enter phase 1 development, while PX130 is in preclinical stages.

The acquisition aims to address the unmet needs of patients with moderate to severe AD and asthma. Approximately 70% of AD patients do not achieve remission with current standard care therapies. Proteologix's bispecific antibodies are designed to target multiple pathways, potentially offering more effective treatment options.

David Lee, Global Immunology Therapeutic Area Head at Johnson & Johnson, expressed optimism for the best-in-disease efficacy for both PX128 and PX130, citing their ability to target distinct combinations of disease-driving pathways.

The merger also includes other bispecific antibody programs with applications across various diseases, enhancing Johnson & Johnson's ability to create novel treatments.

Candice Long, Worldwide Vice President of Immunology at Johnson & Johnson, emphasized the company's commitment to expanding its reach for individuals living with immune-mediated diseases by integrating Proteologix's bispecific antibodies into their pipeline.

AD, a chronic inflammatory skin disorder, affects over 100 million adults globally, while asthma impacts 262 million people worldwide. Both conditions can significantly deteriorate patients' quality of life.

The transaction is expected to be accounted for as a business combination, with no anticipated impact on Johnson & Johnson's 2024 adjusted EPS guidance range.

The information in this article is based on a press release statement from Johnson & Johnson.

InvestingPro Insights

As Johnson & Johnson (NYSE: JNJ) forges ahead with its strategic acquisition of Proteologix, Inc., the company's financial health and market position remain robust. With a formidable market capitalization of $367.43 billion, Johnson & Johnson is a heavyweight in the pharmaceutical industry. The company's commitment to innovation and patient care is reflected in its significant revenue growth over the last twelve months as of Q1 2024, recording a 10.57% increase.

An InvestingPro Tip worth noting is Johnson & Johnson's impressive track record of raising its dividend for 54 consecutive years, showcasing a strong commitment to shareholder returns. This is complemented by the company's low price volatility, making it a potentially attractive option for investors seeking stability in their portfolio.

On the financial front, the company's P/E ratio stands at 9.84, indicating that its stock could be undervalued compared to earnings. Johnson & Johnson also boasts a healthy dividend yield of 3.25%, which is a testament to its ability to generate cash flow and reward its shareholders consistently.

For those interested in further insights and tips, InvestingPro offers 10 additional InvestingPro Tips for Johnson & Johnson, which can be accessed at To gain deeper analysis and metrics, use the coupon code PRONEWS24 for an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.